Acute Respiratory Distress Syndrome; A Review of Recent Updates and a Glance into the Future
- PMID: 37174920
- PMCID: PMC10177247
- DOI: 10.3390/diagnostics13091528
Acute Respiratory Distress Syndrome; A Review of Recent Updates and a Glance into the Future
Abstract
Acute respiratory distress syndrome (ARDS) is a rapidly progressive form of respiratory failure that accounts for 10% of admissions to the ICU and is associated with approximately 40% mortality in severe cases. Despite significant mortality and healthcare burden, the mainstay of management remains supportive care. The recent pandemic of SARS-CoV-2 has re-ignited a worldwide interest in exploring the pathophysiology of ARDS, looking for innovative ideas to treat this disease. Recently, many trials have been published utilizing different pharmacotherapy targets; however, the long-term benefits of these agents remain unknown. Metabolomics profiling and stem cell transplantation offer strong enthusiasm and may completely change the outlook of ARDS management in the near future.
Keywords: acute respiratory distress syndrome; gut-lung microbiome; mesenchymal stem cell transplantation; metabolomics; pharmacotherapy in ARDS.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Diamond M., Peniston H.L., Sanghavi D., Mahapatra S. Acute Respiratory Distress Syndrome. StatPearls Publishing; Tampa, FL, USA: 2022. - PubMed